Gilead Sciences announced that the U.S. Food and Drug Administration accepted its New Drug Application for a once‑daily single‑tablet combination of bictegravir 75 mg and lenacapavir 50 mg, a novel HIV treatment for virologically suppressed adults. The FDA granted the application priority review, a designation that shortens the review period to six months and signals the agency’s recognition of the therapy’s potential to address an unmet need in HIV care.
The acceptance of the NDA on April 29 2026 places Gilead on a clear path toward approval, with a projected PDUFA action date of August 27 2026. The bictegravir/lenacapavir combination merges an integrase strand transfer inhibitor with a first‑in‑class capsid inhibitor, offering a high‑barrier, once‑daily regimen that could appeal to patients seeking to streamline complex multi‑tablet regimens or those with prior antiretroviral resistance.
Gilead’s existing HIV portfolio, anchored by Biktarvy, has generated $13.4 billion in sales in 2024. The new combination is expected to strengthen the company’s long‑term revenue pipeline by adding a differentiated product that can capture market share from patients who need a simplified regimen or who have experienced resistance to other therapies. Management emphasized the strategic fit: "This once‑daily, single‑tablet regimen brings together the high barrier to resistance of bictegravir with lenacapavir, a first‑in‑class capsid inhibitor with a novel mechanism of action that has no cross‑resistance with other antiretrovirals," said Dietmar Berger, M.D., Ph.D., Chief Medical Officer.
The FDA’s priority‑review designation reflects the agency’s view that the combination offers a meaningful advance in HIV treatment. Analysts note that the approval would reinforce Gilead’s leadership in the HIV market and provide a new source of growth as the company continues to face competition from other antiretroviral therapies and evolving market dynamics. The announcement was well received by the market, with investors recognizing the potential for a new, streamlined regimen to broaden Gilead’s product portfolio and sustain its revenue growth trajectory.
The company’s financial performance in recent years has been driven by its core HIV products, with HIV product sales increasing 6% to $20.8 billion in full‑year 2025. The addition of bictegravir/lenacapavir is positioned to maintain this momentum, offering a high‑barrier, once‑daily option that could attract patients who are aging, have comorbidities, or seek novel treatment options. Gilead’s management remains confident that the new therapy will complement its existing portfolio and support continued growth in the HIV segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.